Kynurenine pathway in schizophrenia: pathophysiological and therapeutic aspects.

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Current pharmaceutical design

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.2174/138161211795049552PMID 21361867
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cortical kynurenine pathway metabolism: a novel target for cognitive enhancement in Schizophrenia.

  2010cited by this paper
• Dopamine and psychosis: theory, pathomechanisms and intermediate phenotypes.

  2010cited by this paper
• Long-chain omega-3 fatty acids for indicated prevention of psychotic disorders: a randomized, placebo-controlled trial.

  2010cited by this paper
• Adjuvant aspirin therapy reduces symptoms of schizophrenia spectrum disorders: results from a randomized, double-blind, placebo-controlled trial.

  2010cited by this paper
• Haloperidol and clozapine decrease S100B release from glial cells.

  2010cited by this paper
• Pharmacological Manipulation of Kynurenic Acid

  2009cited by this paper
• Cytokine Changes and Tryptophan Metabolites in Medication-Naïve and Medication-Free Schizophrenic Patients

  2009cited by this paper
• Atypical neuroleptic risperidone modulates glial functions in C6 astroglial cells.

  2009cited by this paper
• Neuroinflammation in Schizophrenia-Related Psychosis: A PET Study

  2009cited by this paper
• Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology.

  2008cited by this paper
• Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review.

  2008cited by this paper
• Neuroleptic treatment increases soluble IL-2 receptors and decreases soluble IL-6 receptors in schizophrenia

  2008cited by this paper
• D-serine serum levels in patients with schizophrenia: relation to psychopathology and comparison to healthy subjects.

  2008cited by this paper
• Possible anti-catatonic effects of minocycline in patients with schizophrenia.

  2007cited by this paper
• Regulation of the GABA cell phenotype in hippocampus of schizophrenics and bipolars

  2007cited by this paper
• Astrocytes are active players in cerebral innate immunity.

  2007cited by this paper
• Upregulation of the initiating step of the kynurenine pathway in postmortem anterior cingulate cortex from individuals with schizophrenia and bipolar disorder.

  2006cited by this paper
• First in vivo evidence of an NMDA receptor deficit in medication-free schizophrenic patients

  2006cited by this paper
• Cytokines in schizophrenia and the effects of antipsychotic drugs.

  2006cited by this paper
• Grey matter changes can improve the prediction of schizophrenia in subjects at high risk

  2006cited by this paper
• Chronic neuroleptic treatment reduces endogenous kynurenic acid levels in rat brain

  2006cited by this paper
• Molecular and cellular mechanisms of altered GAD1/GAD67 expression in schizophrenia and related disorders.

  2006cited by this paper
• The Neurochemical Circuitry of Schizophrenia

  2006cited by this paper
• Kurt Snyder's personal experience with schizophrenia.

  2006cited by this paper
• Reduced D-serine to total serine ratio in the cerebrospinal fluid of drug naive schizophrenic patients.

  2005cited by this paper
• Expression of indoleamine 2,3‐dioxygenase and production of quinolinic acid by human microglia, astrocytes, and neurons

  2005cited by this paper
• Relation of plasma glycine, serine, and homocysteine levels to schizophrenia symptoms and medication type.

  2005cited by this paper
• Cortical inhibitory neurons and schizophrenia

  2005cited by this paper
• Maternal immune activation leads to behavioral and pharmacological changes in the adult offspring.

  2005cited by this paper
• Duration of illness and treatment effects on hippocampal volume in male patients with schizophrenia

  2005cited by this paper
• Elevated plasma prostaglandin E2 levels in schizophrenia

  2005cited by this paper
• Elevated glutamine/glutamate ratio in cerebrospinal fluid of first episode and drug naive schizophrenic patients

  2005cited by this paper
• Investigations of cytokine production in whole blood cultures of paranoid and residual schizophrenic patients

  2005cited by this paper
• Prostaglandin-mediated control of rat brain kynurenic acid synthesis – opposite actions by COX-1 and COX-2 isoforms

  2005cited by this paper
• Mechanism of action of antipsychotic drugs: from dopamine D(2) receptor antagonism to glutamate NMDA facilitation.

  2005cited by this paper
• Prenatal developmental disturbances in the limbic allocortex in schizophrenics

  2005cited by this paper
• Prediction of the ability of clozapine to treat negative symptoms from plasma glycine and serine levels in schizophrenia.

  2005cited by this paper
• Clinical effects of COX–2 inhibitors on cognition in schizophrenia

  2005cited by this paper
• Childhood meningitis, brain maturation and the risk of psychosis*

  2004cited by this paper
• Th1, Th2 and Th3 cytokine alteration in schizophrenia.

  2004cited by this paper
• Childhood central nervous system infections and risk for schizophrenia

  2004cited by this paper
• Neuronal expression of cyclooxygenase-2, a pro-inflammatory protein, in the hippocampus of patients with schizophrenia.

  2004cited by this paper
• COX-2 inhibition as a treatment approach in schizophrenia: Immunological considerations and clinical effects of celecoxib add-on therapy

  2004cited by this paper
• Antibodies to infectious agents in individuals with recent onset schizophrenia

  2004cited by this paper
• Serologic evidence of prenatal influenza in the etiology of schizophrenia.

  2004cited by this paper
• Plasma glycine and serine levels in schizophrenia compared to normal controls and major depression: relation to negative symptoms.

  2004cited by this paper
• Psychotropic Effects of COX-2 Inhibitors - A Possible New Approach for the Treatment of Psychiatric Disorders

  2004cited by this paper
• Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia.

  2003cited by this paper
• Kynurenic acid and schizophrenia.

  2003cited by this paper
• Inhibition of COX‐2 reduces the age‐dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat

  2002cited by this paper
• Endogenous kynurenines as targets for drug discovery and development

  2002cited by this paper
• Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.

  2002cited by this paper
• Kynurenic acid levels are elevated in the cerebrospinal fluid of patients with schizophrenia.

  2001cited by this paper
• Schizophrenia and viral infection during neurodevelopment: a focus on mechanisms

  2001cited by this paper
• T-helper-1 and T-helper-2 responses in psychiatric disorders.

  2001cited by this paper
• Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection

  2001cited by this paper
• Increased cortical kynurenate content in schizophrenia.

  2001cited by this paper
• Pharmacological elevation of endogenous kynurenic acid levels activates nigral dopamine neurons

  2001cited by this paper
• Synthesis and release of neurotoxic kynurenine metabolites by human monocyte-derived macrophages.

  2001cited by this paper
• Maternal infections and subsequent psychosis among offspring.

  2001cited by this paper
• The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications.

  2001cited by this paper
• Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence.

  2001cited by this paper
• Decreased levels of soluble intercellular adhesion molecule-1 (sICAM-1) in unmedicated and medicated schizophrenic patients.

  2000cited by this paper
• Decrease in reelin and glutamic acid decarboxylase67 (GAD67) expression in schizophrenia and bipolar disorder: a postmortem brain study.

  2000cited by this paper
• Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia.

  2000cited by this paper
• Neuronal Activity and Brain-Derived Neurotrophic Factor Regulate the Density of Inhibitory Synapses in Organotypic Slice Cultures of Postnatal Hippocampus

  2000cited by this paper
• Increase in expression of adhesion molecule receptors on T helper cells during antipsychotic treatment and relationship to blood-brain barrier permeability in schizophrenia.

  1999cited by this paper
• Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

  1999cited by this paper
• Exposure to prenatal and childhood infections and the risk of schizophrenia: suggestions from a study of sibship characteristics and influenza prevalence.

  1999cited by this paper
• 3‐Hydroxykynurenine, an Endogenous Oxidative Stress Generator, Causes Neuronal Cell Death with Apoptotic Features and Region Selectivity

  1998cited by this paper
• Increased arachidonic acid induced platelet chemiluminescence indicates cyclooxygenase overactivity in schizophrenic subjects.

  1998cited by this paper
• Cytokines production in chronic schizophrenia patients with or without paranoid behaviour.

  1998cited by this paper
• Seasonality of births in schizophrenia and bipolar disorder: a review of the literature.

  1997cited by this paper
• In vivo immunomodulatory effects of clozapine in schizophrenia.

  1997cited by this paper
• Different kynurenine pathway enzymes limit quinolinic acid formation by various human cell types.

  1997cited by this paper
• (R,S)-3,4-dichlorobenzoylalanine (FCE 28833A) causes a large and persistent increase in brain kynurenic acid levels in rats.

  1996cited by this paper
• Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects.

  1996cited by this paper
• Fibrin degradation products in post mortem brain tissue of schizophrenics: a possible marker for underlying inflammatory processes.

  1996cited by this paper
• Kynurenine Disposition in Blood and Brain of Mice: Effects of Selective Inhibitors of Kynurenine Hydroxylase and of Kynureninase

  1996cited by this paper
• Effects of MK-801 on spontaneous and amphetamine-stimulated dopamine release in striatum measured with in vivo microdialysis in awake rats.

  1996cited by this paper
• Glutamate receptor dysfunction and schizophrenia.

  1995cited by this paper
• Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

  1994cited by this paper
• Neuropharmacology of quinolinic and kynurenic acids.

  1993cited by this paper
• A mechanism of quinolinic acid formation by brain in inflammatory neurological disease. Attenuation of synthesis from L-tryptophan by 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.

  1993cited by this paper
• Hypofrontality in neuroleptic-naive patients and in patients with chronic schizophrenia. Assessment with xenon 133 single-photon emission computed tomography and the Tower of London.

  1992cited by this paper
• Human microglia convert l-tryptophan into the neurotoxin quinolinic acid.

  1992cited by this paper
• Dopamine in schizophrenia: a review and reconceptualization.

  1991cited by this paper
• A Glycine Site Associated with N‐Methyl‐d‐Aspartic Acid Receptors: Characterization and Identification of a New Class of Antagonists

  1989cited by this paper
• Interferons and indoleamine 2,3-dioxygenase: Role in antimicrobial and antitumor effects

  1989cited by this paper
• Implications of normal brain development for the pathogenesis of schizophrenia.

  1987cited by this paper
• Interferon enhances tryptophan metabolism by inducing pulmonary indoleamine 2,3-dioxygenase: its possible occurrence in cancer patients.

  1986cited by this paper
• Kynurenine hydroxylase: a potential rate-limiting enzyme in tryptophan metabolism.

  1985cited by this paper
• [The concept of substrate-close basic symptoms and its significance for the theory and therapy of schizophrenic diseases].

  1983cited by this paper
• Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain.

  1983cited by this paper
• l-Kynurenine Its synthesis and possible regulatory function in brain

  1980cited by this paper
• Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia.

  1980cited by this paper
• Brain receptors for antipsychotic drugs and dopamine: direct binding assays.

  1975cited by this paper
• [Influence of therapy on antibody-formation].

  1971cited by this paper

• Targeting neurochemical and immune dysregulation in schizophrenia: From molecular mechanisms to emerging therapeutic strategies.

  2025cites this paper
• Developing a risk assessment model for treatment-resistant schizophrenia: The role of niacin receptor GPR109A and prostaglandin receptors DP1, EP2, and EP4 in the niacin-induced flushing pathway.

  2025cites this paper
• Molecular Underpinning of Treatment-Resistant Schizophrenia: A Putative Different Neurobiology from Treatment-Responsive Schizophrenia

  2025cites this paper
• Hematological and inflammatory markers in Han Chinese patients with drug-free schizophrenia: relationship with symptom severity

  2024cites this paper
• Human-fecal microbiota transplantation in relation to gut microbiome signatures in animal models for schizophrenia: A scoping review.

  2024cites this paper
• Kynurenic Acid/AhR Signaling at the Junction of Inflammation and Cardiovascular Diseases

  2024cites this paper
• Indoleamine 2,3-dioxygenase (IDO1) - Can dendritic cells and monocytes expressing this moonlight enzyme change the phase of Parkinson's Disease?

  2024cites this paper
• Neuroinflammation in the Evolution of Motor Function in Stroke and Trauma Patients: Treatment and Potential Biomarkers

  2023cites this paper
• The Relevance of Animal Models of Social Isolation and Social Motivation for Understanding Schizophrenia: Review and Future Directions.

  2023cites this paper
• The kynurenine pathway in traumatic brain injuries and concussion

  2023cites this paper
• IDO/Kynurenine; novel insight for treatment of inflammatory diseases.

  2023cites this paper
• Toll-Like Receptor 4 Gene Polymorphisms and Susceptibility to Schizophrenia: A Case-Control Study

  2022cites this paper
• Inflammation Subtypes and Translating Inflammation-Related Genetic Findings in Schizophrenia and Related Psychoses: A Perspective on Pathways for Treatment Stratification and Novel Therapies

  2022cites this paper
• Linking Inflammation, Aberrant Glutamate-Dopamine Interaction, and Post-synaptic Changes: Translational Relevance for Schizophrenia and Antipsychotic Treatment: a Systematic Review

  2022cites this paper
• Association between TLR2 polymorphisms (− 196–174 Ins/Del, R677W, R753Q, and P631H) and schizophrenia in a Tunisian population

  2021cites this paper
• Inflammation and Immunity in Schizophrenia

  2021cites this paper
• Galantamine-Memantine Combination and Kynurenine Pathway Enzyme Inhibitors in the Treatment of Neuropsychiatric Disorders

  2021cites this paper
• Immune Influencers in Action: Metabolites and Enzymes of the Tryptophan-Kynurenine Metabolic Pathway

  2021cites this paper
• Current challenges and possible future developments in personalized psychiatry with an emphasis on psychotic disorders

  2020cites this paper
• Effects of inflammation on the kynurenine pathway in schizophrenia — a systematic review

  2020cites this paper
• A mood state‐specific interaction between kynurenine metabolism and inflammation is present in bipolar disorder

  2020cites this paper
• Bio-behavioural evaluation of efavirenz and Δ9-tetrahydrocannabinol alone and in combination in rats with respect to psychosis and anxiety

  2019cites this paper
• Schizophrenia phenomenology comprises a bifactorial general severity and a single-group factor, which are differently associated with neurotoxic immune and immune-regulatory pathways

  2019cites this paper
• Galantamine-Memantine Combination as an Antioxidant Treatment for Schizophrenia

  2019cites this paper
• Red-emitting gold nanoclusters for rapid fluorescence sensing of tryptophan metabolites

  2019cites this paper
• Age-related changes in neuroinflammation and prepulse inhibition in offspring of rats treated with Poly I:C in early gestation

  2019cites this paper
• Kynurenines and the Endocannabinoid System in Schizophrenia: Common Points and Potential Interactions

  2019influential citation
• Pharmacotherapy of schizophrenia: toward a metabolomic-based approach

  2018cites this paper
• Inflammation in Schizophrenia: Pathogenetic Aspects and Therapeutic Considerations

  2018cites this paper
• METABOLISMO DO TRIPTOFANO EM TRANSTORNOS MENTAIS: UM ENFOQUE NA ESQUIZOFRENIA

  2017influential citation
• Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial

  2017cites this paper
• Pharmacotherapy in Generalized Anxiety Disorder: Novel Experimental Medicine Models and Emerging Drug Targets

  2017cites this paper
• Consensus paper of the WFSBP Task Force on Biological Markers: Criteria for biomarkers and endophenotypes of schizophrenia, part III: Molecular mechanisms

  2017cites this paper
• Kynurenic Acid in Schizophrenia: A Systematic Review and Meta-analysis

  2017cites this paper
• Association of the IFN-γ (+874A/T) Genetic Polymorphism with Paranoid Schizophrenia in Tunisian Population

  2017cites this paper
• Effect of Neuroinflammation on Synaptic Organization and Function in the Developing Brain: Implications for Neurodevelopmental and Neurodegenerative Disorders

  2017cites this paper
• IFNGR2 genetic polymorphism associated with sex-specific paranoid schizophrenia risk

  2017cites this paper
• Involvement of the kynurenine pathway in the pathogenesis of Parkinson's disease

  2017cites this paper
• Oral administration of a specific kynurenic acid synthesis (KAT II) inhibitor attenuates evoked glutamate release in rat prefrontal cortex.

  2017cites this paper
• The Microbiota and Gut-Brain Axis: Contributions to the Immunopathogenesis of Schizophrenia.

  2016cites this paper
• Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A "central hub" in schizophrenia pathophysiology?

  2016cites this paper
• Kynurenines, Gender and Neuroinflammation; Showcase Schizophrenia

  2016cites this paper
• Evidence for increased immune mobilization in First Episode Psychosis compared with the prodromal stage in males.

  2016cites this paper
• A classifier driven approach to find biomarkers for affective disorders from transcription profiles in blood

  2016cites this paper
• Social Isolation Rearing and Sensorimotor Gating in Rat Models of Relevance to Schizophrenia: What We Know, and What We Do Not Know

  2016cites this paper
• The Role of Inflammation and the Immune System in Schizophrenia

  2016cites this paper
• Behavioral sequelae of astrocyte dysfunction: focus on animal models of schizophrenia.

  2016cites this paper
• The Carnitine Palmitoyl Transferase (CPT) System and Possible Relevance for Neuropsychiatric and Neurological Conditions

  2015cites this paper
• Tryptophan-kynurenine pathway is dysregulated in inflammation, and immune activation.

  2015cites this paper
• The Next Decade in Tryptophan Metabolism Research

  2015cites this paper
• Simultaneous determination of multiple neurotransmitters and their metabolites in rat brain homogenates and microdialysates by LC-MS/MS

  2015cites this paper
• 3-Hydroxykynurenic Acid and Type 2 Diabetes: Implications for Aging, Obesity, Depression, Parkinson’s Disease, and Schizophrenia

  2015cites this paper
• The role of inflammation in schizophrenia

  2015cites this paper
• Cytokine profile in drug-naïve, first episode patients with psychosis.

  2015cites this paper
• Humans as Superorganisms

  2015cites this paper
• Neuronal Carnitine Palmitoyl Transferase1c in the Central Nervous System: Current Visions and Perspectives

  2014cites this paper
• Dysregulation of the kynurenine pathway in psychotic disorders : immunological aspects

  2014cites this paper
• The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia.

  2014cites this paper
• Contemporary anti-inflammatory treatment approaches

  2014cites this paper
• Infectious Diseases and Mental Health

  2014cites this paper
• Quinolinate and related excitotoxins: mechanisms of neurotoxicity and disease relevance

  2014cites this paper
• Der Einfluss von Clozapin, N-Desmethylclozapin und Chlorpromazin auf die in-vitro-Produktion von Thromboxan

  2014cites this paper
• Targeting of NMDA receptors in new treatments for schizophrenia

  2014cites this paper
• Neuroinflammation: Contemporary anti-inflammatory treatment approaches.

  2014cites this paper
• Role of immunological factors in the pathophysiology and diagnosis of bipolar disorder: Comparison with schizophrenia

  2014cites this paper
• Metabolic consequences of interleukin-6 challenge in developing neurons and astroglia

  2014cites this paper
• Immunology of Schizophrenia

  2014cites this paper
• Developmental neuroinflammation and schizophrenia.

  2013cites this paper
• Toxoplasma gondii infection and behaviour – location, location, location?

  2013cites this paper
• Schizophrenia: Linking prenatal infection to cytokines, the tryptophan catabolite (TRYCAT) pathway, NMDA receptor hypofunction, neurodevelopment and neuroprogression

  2013cites this paper
• Putative neuroprotective agents in neuropsychiatric disorders.

  2013cites this paper
• Interleukin 18 and cognitive impairment in first episode and drug naïve schizophrenia versus healthy controls.

  2013cites this paper
• Mechanisms of Involvement of Eicosanoids and their Precursors in the Pathophysiology and Treatment of Schizophrenia.

  2013cites this paper
• The question of pro-inflammatory immune activity in schizophrenia and the potential importance of anti-inflammatory drugs.

  2013cites this paper
• Increased cerebrospinal fluid interleukin-6 levels in patients with schizophrenia and those with major depressive disorder.

  2013cites this paper
• The mild encephalitis concept for psychiatric disorders revisited in the light of current psychoneuroimmunological findings

  2013cites this paper
• Characterization of a rat model of Maternal Immune Activation with relevance to schizophrenia in terms of maternal and foetal cytokine responses, adult behavioural outcome and chronic brain inflammation

  2013cites this paper
• Neuroinflammation and depression: the role of indoleamine 2,3-dioxygenase (IDO) as a molecular pathway.

  2012cites this paper
• Morphological features of microglial cells in the hippocampal dentate gyrus of Gunn rat: a possible schizophrenia animal model

  2012cites this paper
• Phenotypic effects of repeated psychosocial stress during adolescence in mice mutant for the schizophrenia risk gene neuregulin-1: a putative model of gene × environment interaction.

  2012cites this paper
• The kynurenine system and immunoregulation

  2012cites this paper
• Quantitative analysis of neurochemical panel in rat brain and plasma by liquid chromatography-tandem mass spectrometry.

  2012cites this paper
• Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review.

  2012cites this paper
• Kynurenic acid and 3-hydroxykynurenine production from D-kynurenine in mice.

  2012cites this paper
• A concise preparation of the non-proteinogenic amino acid l-kynurenine

  2012cites this paper
• In vivo immunomodulatory effects of antipsychotics on inflammatory mediators: A review

  2012cites this paper
• Novel potential therapeutic approaches for schizophrenia.

  2011cites this paper
• Anti-inflammatory signaling in schizophrenia.

  2011cites this paper
• Comparative immunogenetics of autism and schizophrenia

  2011cites this paper
• Recent advances in psychoneuroimmunology: Inflammation in psychiatric disorders

  2011cites this paper